Synta shares rise on disclosure of updated plans for cancer drug

Shares of Synta Pharmaceuticals saw a modest bounce today after the company announced — with no mention of the recent sudden departure of its co-founder and longtime CEO — financial results for 2013 and updates on trials of its most advanced cancer-drug candidate, ganetespib...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.